Adherence to combination therapy enhances sustained response in genotype-1–infected patients with chronic hepatitis C

McHutchison, John G.; Manns, Michael P.; Patel, Keyur; Poynard, Thierry; Lindsay, Karen L.; Trépo, Christian; Dienstag, Jules L.; Lee, William M.; Mak, Carmen; Garaud, Jean–Jacques; Albrecht, Janice K.

doi:10.1053/gast.2002.35950

Cited by 900 publications

(763 citation statements)

References 18 publications

Supporting

Mentioning

705

Contrasting

Unclassified

Order By: Relevance

“…In patients with CHC it is extremely important to ensure complete adherence to therapy with peg-IFN and RBV in order to achieve therapeutic success (greater percentage of SVR). Indeed, early interruption of therapy or reduction of peg-IFN or RBV dose because of side effects, leads to a significant decrease in SVR [21,[41][42][43].…”

Section: Resultsmentioning

confidence: 99%

Epoetin alpha improves the response to antiviral treatment in HCV-related chronic hepatitis

Bertino

Ardiri

Boemi

et al. 2010

Eur J Clin Pharmacol

View full text Add to dashboard Cite

show abstract

Section: Resultsmentioning

confidence: 99%

Epoetin alpha improves the response to antiviral treatment in HCV-related chronic hepatitis

Bertino

Ardiri

Boemi

et al. 2010

Eur J Clin Pharmacol

View full text Add to dashboard Cite

show abstract

“…Attaining SVR is critical to achieving long-term HRQL in patients with CHC. 60,61 However, the side effects of combination therapy, which can compromise HRQL, increase the likelihood that patients will discontinue treatment before realizing the benefits. Data from McHutchison et al 60 suggest that adherence to combination therapy in patients with CHC must be maintained to maximize antiviral response and to achieve SVR.…”

Section: Side Effects Of Chc Treatment and Their Managementmentioning

confidence: 99%

“…60,61 However, the side effects of combination therapy, which can compromise HRQL, increase the likelihood that patients will discontinue treatment before realizing the benefits. Data from McHutchison et al 60 suggest that adherence to combination therapy in patients with CHC must be maintained to maximize antiviral response and to achieve SVR. Bernstein et al 61 found that SVR is associated with HRQL improvements as measured by the SF-36 and Fatigue Severity Scale and that these improvements were evident in patients with advanced liver disease.…”

Section: Side Effects Of Chc Treatment and Their Managementmentioning

confidence: 99%

See 1 more Smart Citation

The effects of HCV infection and management on health-related quality of life

2007

View full text Add to dashboard Cite

“…The combination therapy of peginterferon-alpha and ribavirin has been widely recommended as a first choice for chronic hepatitis C patients with high virus-load (1)(2)(3)(4)(5). However, one big problem of the combination therapy is the treatment-related side effect (6,7).…”

Section: Introductionmentioning

confidence: 99%

Efficacy and Safety of Combination Therapy of Natural Human Interferon Beta and Ribavirin in Chronic Hepatitis C patients

Arase

Suzuki

et al. 2011

Intern. Med.

View full text Add to dashboard Cite

Objective The aim of this study was to evaluate the efficacy and safety of combination therapy of natural human interferon-beta and ribavirin for patients for whom prior interferon therapy was discontinued due to depression induced by interferon-alpha. Methods Inclusion criteria were as follows; 1) HCV-genotype 1b, 2) serum HCV RNA level of !100 KIU/mL, 3) stopping the prior interferon-alpha monotherapy or combination therapy of interferon-alpha and ribavirin due to the appearance of depression. A total of 14 were enrolled in this prospective cohort study. The treatment period of combination therapy was 48 weeks. Depression states, reflected by Beck depression inventories and Hamilton depression rating scale, were assessed during combination therapy. Nonparametric procedures were employed for the analysis of background features of the patients with sustained virological response (SVR) and without SVR. A p value of <0.05 was considered to indicate a significant difference. Results Five of 14 patients (37.5%) had SVR by the intention to treat analysis. The SVR rate in patients who showed negative HCV RNA at 12 and 24 weeks after the initiation of combination therapy was 100% (4/4) and 83.3% (5/6), respectively. All of the patients continued the combination therapy owing to disappearance of severely adverse events contained the exacerbation of depression. Combination therapy did not yield a statistical difference in Beck depression inventories and Hamilton depression rating scale. Conclusion The combination therapy of IFN-beta and ribavirin is a possible therapy selection for the patients for whom interferon therapy was discontinued due to depression induced by interferon-alpha.

show abstract

Adherence to combination therapy enhances sustained response in genotype-1–infected patients with chronic hepatitis C

Cited by 900 publications

References 18 publications

Epoetin alpha improves the response to antiviral treatment in HCV-related chronic hepatitis

Epoetin alpha improves the response to antiviral treatment in HCV-related chronic hepatitis

The effects of HCV infection and management on health-related quality of life

Efficacy and Safety of Combination Therapy of Natural Human Interferon Beta and Ribavirin in Chronic Hepatitis C patients

Contact Info

Product

Resources

About